Biogen Inc. reported quarterly revenue and adjusted earnings that beat analysts’ expectations as sales of newly acquired kidney and eye-disease drugs helped offset declining revenue from multiple sclerosis medicines.
Formation Bio has appointed Michael Ehlers, the former research head at Biogen Inc., as its chief scientific officer. This move brings a seasoned drug and biotech veteran into the AI-focused health startup.
Biogen's leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, backing up the pharma’s decision to race the molecule into phase 3 development.
Biogen's leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, backing up the pharma’s decision to race the molecule into phase 3 development.
Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio
Biogen Cuts FY Adjusted View as Profit Declines
Biogen beats quarterly estimates as newer drugs fuel growth
Biogen Raises Earnings Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs
Why Is Biogen Stock Falling Tuesday?
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
This Biogen Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday